Clinical importance of determination of procalcitonin in diagnosis of sepsis
https://doi.org/10.33667/2078-5631-2021-32-30-34
Abstract
The review presents an assessment of the dynamics of the change in procalcitonin as the main marker of bacterial inflammation in patients with the syndrome of systemic inflammatory reaction, sepsis and septic shock, clarification of the practical and predictive significance of PCT in patients with an identified and not identified focus of infection.
About the Authors
S. S. Bayramova
Research Institute for Therapy and Preventive Medicine – a Branch of Federal Research Centre of Institute for Cytology and Genetics of the Siberian branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Bayramova Sabina S., junior researcher of Emergency Care Laboratory
Novosibirsk
O. V. Tsygankova
Research Institute for Therapy and Preventive Medicine – a Branch of Federal Research Centre of Institute for Cytology and Genetics of the Siberian branch of Russian Academy of Sciences; Novosibirsk State Medical University
Russian Federation
Russian Federation
Tsygankova Oksana V., DM Sci, professor at Dept of Emergency Therapy with Endocrinology and Occupational Pathology; senior researcher of Laboratory for Clinical Biochemical and Hormonal Research of Therapeutic Diseases
Novosibirsk
K. Yu. Nikolayev
Research Institute for Therapy and Preventive Medicine – a Branch of Federal Research Centre of Institute for Cytology and Genetics of the Siberian branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Nikolaev Konstantin Yu., DM Sci, professor, head of Emergency Care Laboratory
Novosibirsk
O. V. Tuzovskaya
Research Institute for Therapy and Preventive Medicine – a Branch of Federal Research Centre of Institute for Cytology and Genetics of the Siberian branch of Russian Academy of Sciences
Russian Federation
Russian Federation
Tuzovskaya Olga Viktorovna, resident of the laboratory of molecular genetic studies of therapeutic diseases
Novosibirsk
References
1. Ramirez JA, Wiemken TL, Peyrani P, et al. University of Louisville Pneumonia Study Group. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clinical Infectious Diseases. 2017; 65 (11): 1806–12. DOI: 10.1093/ofid/ofx163.1493.
2. Bilichenko T. N., Chuchalin A. G. Morbidity and mortality of the population of Russia from acute respiratory viral infections, pneumonia and vaccine prevention. Therapeutic archive. 2018; (1): 22–26. DOI: 10.17116/terarkh201890122–26.
3. Rudnov V. A. Evolution of ideas about sepsis: history continues. Infections in surgery. 2015; 13 (2): 6–10.
4. Alibayeva K. M. Analysis of the quantitative determination of the level of C-reactive protein and procalcitonin in patients with infectious pathology. Bulletin of the Almaty state institute for improving doctors. 2015; 1–2: 36–40.
5. Boronina L. G. Five-year experience of using a quantitative study of procalcitonin in the diagnosis of bacteremia and sepsis. Bulletin of the Ural Medical Academic Science. 2015; 4: 5–39.
6. Ashitha L. Vijayan. Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy. Journal of Intensive Care. 2017; 1–7. DOI: 10.1186/s40560–017–0246–8.
7. Yakubtsevich R. E. Sepsis in intensive care: modern aspects of diagnosis. Journal of Grodno State Medical University. 2016; 1: 11–16.
8. Kulabukhov V. V. Comparison of the diagnostic potential of sepsis biomarkers in patients with thermal injury. Infections in surgery. 2015; 3: 38–48.
9. Domonkos Trásy and Zsolt Molnár. Procalcitonin – Assisted Antibiotic Strategy in Sepsis. EJIFCC. 2017; 28 (2): 104–113.
10. Hongmin Zhang. Comparison of procalcitonin and high sensitivity C-reactive protein for the diagnosis of sepsis and septic shock in the oldest old patients. BMC Geriatrics. 2017; 1–6.
11. Liu G. B., Cui X. Q., Wang Z. B. et al. Detection of serum procalcitonin and hypersensitive C-reactive protein in patients with pneumonia and sepsis. J Biol Regul Homeost Agents. 2018; 32 (5): 1165–1169.
12. Nikolaev K. Yu., Tsygankova O. V., Bayramova S. S. Significance of the new semi-quantitative rapid procalcitonin test in determining the severity of community-acquired pneumonia. Medical alphabet. 2020; 1: 37–39. DOI: 10.33667/2078–5631–2020–27–11–13.
13. Karhu J., Ala-Kokko T.I., Vuorinen T. et al. Interleukin‑5, interleukin‑6, interferon induced protein‑10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. Cytokine. 2019; 113: 272–276. DOI: 10.1016/j.cyto.2018.07.019.
14. Titova E. A. Procalcitonin in inflammatory diseases. Medical sciences. 2016; 1: 44.
15. Bayramova S.S., Nikolaev K.Yu., Tsygankova O.V. Application of a new semi-calculous rapid test for procalcitonin in the diagnosis of polysegmental community-acquired pneumonia. Therapeutic archive. 2021; 93 (3). DOI: 10.26442/00403660.2021.03.200654.
16. Malkova O. G. Procalcitonin, bacteremia and infectious complications after cardiac surgery. Clinical experience. 2017; 1: 12–18.
17. Ovsyankina E. S. Test for procalcitonin as a method for predicting bacterial excretion in children and adolescents with respiratory tuberculosis. Zemsky doctor. 2016; 3–4: 18–21.
18. Richard Taylor. A Review of the Value of Procalcitonin as a Marker of Infection. Cureus. 2017; 9 (4): 1–5. DOI: 10.7759/cureus.1148.
19. Zhilinsky E. V. The use of presepsin and procalcitonin in the diagnosis of sepsis in severely burned patients. Emergency medicine. 2015; 3 (15): 35–42.
20. Teplyakova O. V. Informational value of procalcitonin in determining the nature of the inflammatory reaction in rheumatology. Modern rheumatology. 2017; 1: 66–71.
21. Vel'kov V. V. Biomarkers of neonatal sepsis: C-reactive protein, procalcitonin, presepsin. Medical alphabet. 2016; 13: 9–19.
22. Chuchalin A. G. Biological markers in respiratory diseases. Therapeutic archive. 2014; 3: 4–13.
23. Ramirez JA, Wiemken TL, Peyrani P, et al. University of Louisville Pneumonia Study Group. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clinical Infectious Diseases. 2017; 65 (11): 1806–12. DOI: 10.1093/ofid/ofx163.1493.
24. Geppe N. A. Community-acquired pneumonia in children: problems of diagnosis, treatment and prevention. Pediatrics. 2015; 13: 20–27.
25. Rapovka V. G. Modern possibilities of diagnostics of destructive forms of acute pancreatitis. Pacific Medical Journal. 2016; 1: 52–55.
26. Polukhina O. V. The spectrum of bacteremia pathogens in patients with immunodeficiency states of various origins. Infection and immunity. 2014; 4: 43–48.
27. Jose Garnacho-Montero, Irene Barrero-García, Maria de Gracia Gómez-Prieto et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Review of Anti-infective Therapy. 2018; 16 (9): 667–677. DOI: 10.1080/14787210.2018.1512403.
28. Bayramova S. S., Tsygankova O. V., Nikolaev K. Yu., Starichkova A. A. Mechanisms of endothelial dysfunction formation in insulin-resistant states. Medical Alphabet. 2020; 27: 32–36. DOI: 10.33667/2078–5631–2020–27–32–36.
Review
For citations:
Bayramova S.S., Tsygankova O.V., Nikolayev K.Yu., Tuzovskaya O.V. Clinical importance of determination of procalcitonin in diagnosis of sepsis. Medical alphabet. 2021;(32):30-34. (In Russ.) https://doi.org/10.33667/2078-5631-2021-32-30-34
Views:
542
Email this article 